Pen or syringe? study tests easier way to take arthritis drug

NCT ID NCT06946524

Completed Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) enters the body when given by a prefilled pen compared to a prefilled syringe. Fifty-nine healthy adults received a single injection, and researchers measured drug levels and side effects. The goal was to see if the pen delivers the drug as effectively as the syringe, which could make it easier for patients to use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Risankizumab (brand name SKYRIZI)
What this could lead to: If the pen works as well as the syringe, patients may have a more convenient way to take this medication.
What could go wrong: This was a small, early-stage study in healthy volunteers, not patients. Results may not predict real-world use or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Acpru /Id# 275116

Grayslake, Illinois, 60030, United States
Altasciences Clinical Los Angeles /ID# 276446

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.